Utente: Anonimo

'Pharmaceutical Contract Manufacturing Revenues Will Reach $64.07bn in 2016' Says Latest Visiongain's Report

A new report by Visiongain, a London-based business information company, predicts that global contract manufacturing revenues will reach $64.07bn in 2016. Manufacturing of finished dosage forms will drive revenue growth, with the market expected to grow with a CAGR of 8.7% between 2010 and 2016. From 2011 to 2021, revenues for this industry will more than double, according to Pharmaceutical Contract Manufacturing: World Market Outlook 2011-2021, published in August 2011.
LONDON, 15/08/2011 (informazione.it - comunicati stampa - salute e benessere) (/PRNewswire/)

A new report by Visiongain, a London-based business information company, predicts that global contract manufacturing revenues will reach $64.07bn in 2016. Manufacturing of finished dosage forms will drive revenue growth, with the market expected to grow with a CAGR of 8.7% between 2010 and 2016. From 2011 to 2021, revenues for this industry will more than double, according to Pharmaceutical Contract Manufacturing: World Market Outlook 2011-2021, published in August 2011.

API manufacturing remained the largest market sector in 2010, accounting for 71.1% of the total market. API manufacturers in India and China will achieve increasing demand for their services, Visiongain's market analysis shows. Demand for generic and highly potent APIs will drive growth in this market from 2011 to 2021.

Richard Lang, pharmaceutical industry analyst, said: "The global pharmaceutical contract manufacturing industry will benefit from a continued move to strategic outsourcing by the pharmaceutical industry. That industry will look more to long-term relationships with a few selected CMOs as the decade goes on. Becoming a full-service CMO or specialising in a niche area will best allow contract manufacturers to take advantage of these strategic partnerships."

Between 2011 and 2021, demand for contract manufacturing services will continue to come from developed market-based pharmaceutical companies. The US accounted for 42.0% of market demand in 2010. This decade, pharmaceutical companies will outsource increasing amounts of manufacturing, as companies focus on activities such as R&D and marketing. Growth in the biotechnology market will also provide a great opportunity for contract manufacturing organisations (CMOs).

Visiongain forecasts that the overall pharmaceutical contract manufacturing market will grow steadily to 2021. Opportunities exist for CMOs to expand, buying out pharma's facilities or acquiring smaller CMOs to become a "one-stop-shop" for outsourced development and manufacturing. Companies offering specialised manufacturing services will also benefit throughout the decade, the published report concludes. This new study adds to Visiongain's range of analytical reports covering the pharmaceutical outsourcing industry.

Table of Contents
1. Executive Summary
1.1 Pharmaceutical Contract Manufacturing: Market Review
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
2. Introduction to Pharmaceutical Contract Manufacturing
2.1 Pharmaceutical Outsourcing
2.1.1 Contract Research Organisations (CROs)
2.1.2 Contract Manufacturing Organisations (CMOs)
2.1.2.1 Contract Development and Manufacturing Organisations (CDMOs)
2.2 Reasons for Outsourcing Manufacturing
2.2.1 Tactical Outsourcing
2.2.1.1 A Lack of Capacity
2.2.2 Strategic Outsourcing
2.2.2.1 Big Pharma Focusing on Core Competencies
2.2.3 The Rise of Generics
2.2.4 The Rise of Biotechnology
2.2.5 Virtual Companies
3. The Pharmaceutical Contract Manufacturing Market 2011-2021
3.1 The Pharmaceutical Contract Manufacturing Market in 2010
3.1.1 Recent Trends in the Contract Manufacturing Industry and Market
3.2 Pharmaceutical Contract Manufacturing Market Forecast 2011-2021
3.3 Contract API Manufacturing
3.3.1 API Manufacturing Market 2010
3.3.2 API Manufacturing Market Forecast 2011-2021
3.3.3 Highly Potent APIs (HPAPIs)
3.3.3.1 SAFC: Specialising in HPAPIs
3.4 Contract Finished Dosage Form Manufacturing
3.4.1 Finished Dosage Form Market in 2010
3.4.2 Finished Dosage Form Market Forecast 2011-2021
3.4.3 Injectables
4. Leading Contract Manufacturing Organisations in 2011
4.1 A Highly Fragmented Market
4.2 Catalent
4.2.1 Revenues and Recent Performance Analysis
4.2.2 Expanded Oral Delivery Technologies
4.3 Lonza
4.3.1 Revenue and Recent Performance Analysis
4.3.2 Lonza Leveraging its Biologics Expertise
4.3.2.1 Teva and Lonza's Biosimilars Joint Venture
4.4 Royal DSM (DSM)
4.4.1 Revenue and Recent Performance Analysis
4.4.2 Future Outlook
4.5 Boehringer Ingelheim
4.5.1 Revenue and Recent Performance Analysis
4.5.2 Boehringer Acquires Amgen's Biopharmaceutical Facility
4.5.3 Boehringer Partners with Pfenex
4.6 Patheon
4.6.1 Revenue and Recent Performance Analysis
4.6.1.1 Patheon Forms Alliance with India's Kemwell
4.6.2 Expanded Services
4.7 Famar
4.7.1 New Facilities in Spain Expanding Famar's Reach
4.8 Fareva
4.9 Haupt Pharma
4.9.1 Haupt Pharma Increases its Capacity
4.10 Aenova
4.11 Recipharm
4.11.1 Revenue and Recent Performance Analysis
4.11.2 Recipharm's 2010 Acquisitions
4.11.3 Future Growth
4.12 Divis Laboratories
4.12.1 Revenue and Recent Performance Analysis
4.13 Jubilant Life Sciences
4.13.1 Revenue and Recent Performance Analysis
4.14 Piramal Healthcare
4.14.1 Revenue and Recent Performance Analysis
4.14.2 Piramal Seeking to Expand
4.15 Evonik Degussa
4.16 Kemwell
4.16.1 Facility and Service Expansion
5. Contract Manufacturing Industry Trends 2011-2021
5.1 The Decision to Outsource Manufacturing
5.2 Risks in Contract Manufacturing
5.3 Technology Transfer
5.4 Globalisation
5.4.1 The Appeal of Asia
5.5 CMO Proximity
5.6 Surviving in an Increasingly Competitive Market
5.6.1 CMO Consolidation
5.6.2 Strategic Partnering
5.6.3 Buying-Out Pharma's Facilities
5.6.3.1 There Are Risks in Buying-Out Pharma's Facilities
5.6.4 The Risk of Overcapacity
5.6.5 CMO Specialisation as a Way to Compete
5.6.5.1 Lyophilisation
5.6.5.2 Highly Potent APIs and Complex Molecules
5.7 Quality by Design (QbD) and Process Analytical Technology
5.8 CMOs and Biologics
5.8.1 Biosimilars Offer New Opportunities
5.8.2 Therapeutic Peptides Remain a Strong Market Opportunity
5.9 Virtual Companies
5.10 Outsourcing to Emerging Markets
6. Regulatory Developments for Contract Manufacturing 2011-2021
6.1 Good Manufacturing Practice (GMP)
6.1.1 Harmonisation of Global Requirements
6.1.1.1 US, Australian and EU Collaboration
6.2 US Manufacturing Regulations
6.2.1 Recent and Future Developments
6.2.1.1 Foreign API Manufacture
6.3 European Manufacturing Regulations
6.3.1 The Qualified Person
6.3.2 APIs in the EU
6.3.3 Changes to EU GMP Regulations
6.4 GMP in Japan
6.5 Manufacturing Regulations in India
6.6 China: New GMP Regulations for 2011
7. Leading National Contract Manufacturing Markets 2011-2021
7.1 Breakdown of the World Pharmaceutical Market 2010
7.2 The US Market
7.3 The European Market
7.3.1 Germany and France
7.3.2 Italy
7.3.3 Spain
7.3.4 The UK
7.3.4.1 SCM Pharma: An Example of Specialisation
7.4 The Japanese Market
7.4.1 CMIC CMO: a Leading Japanese CMO
7.5 The Indian Market
7.5.1 India as an Outsourcing Destination
7.5.1.1 Indian Intellectual Property
7.6 The Chinese Market
7.6.1 China as an Outsourcing Destination
7.7 Chapter Summary
8. Opinions from Our Survey of the Industry
8.1 Alex Mello, Director of Project Management, Microtest Laboratories
8.1.1 Microtest Laboratories
8.1.2 Technological Developments to Benefit CMOs
8.1.3 Opportunities in the US Contract Manufacturing Market
8.1.4 Restraints in the US Contract Manufacturing Market
8.1.5 Clinical Trial Material Manufacture
8.1.6 CMOs Expanding Their Services
8.2 Hervé Bichon, Vice President, Pharma Sales, Fareva
8.2.1 Technological Developments to Benefit CMOs
8.2.2 Commercial Restraints and Opportunities in the European Pharmaceutical Contract Manufacturing Market
8.2.3 The Role of the Full-Service CMO
8.2.4 South America as an Opportunity
9. Conclusions
9.1 Market Growth 2011-2021
9.1.1 Demand for Contract Manufacturing Will Increase Worldwide
9.1.2 Trend in Outsourcing to Asia Will Continue
9.2 Market Consolidation
9.3 The Rise of Biologics and Biosimilars



Notes for Editors



If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100



About Visiongain


Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.



Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

 

For further information on this report click on:
http://www.visiongain.com/Report/663/Pharmaceutical-Contract-Manufacturing-World-Market-Outlook-2011-2021

Or contact:
Sara Peerun
Sara.peerun@visiongainglobal.com
Tel: +44(0)20-7336-6100
http://www.visiongain.com

Ufficio Stampa
PR Newswire
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili